Tag: kettering

World experts gather for refocusing on patients with small cell lung cancer

| April 14, 2015 | 0 Comments

( International Association for the Study of Lung Cancer ) Small cell lung cancer will be the concentrated focus when 100 global experts in the field meet for a workshop hosted by the International Association for the Study of Lung Cancer on April 22-24, 2015 at Memorial Sloan Kettering Cancer Center in New York City.

Continue Reading

MSK begins CAR T cell clinical trial for children with relapsed or treatment-resistant ALL

| April 12, 2015 | 0 Comments

Researchers from Memorial Sloan Kettering Cancer Center are pioneering a new groundbreaking clinical trial for children and young adults with relapsed or treatment-resistant acute lymphocytic leukemia (ALL) by using one of the most promising methods of cancer treatment today, chimeric antigen receptor (CAR) T cells.

Continue Reading

New cancer treatments target disease-causing mutations

| March 1, 2015 | 0 Comments

Watch Video | Listen to the Audio HARI SREENIVASAN: Some cutting-edge research is giving new hope to cancer patients.

Continue Reading

Mirati Therapeutics Doses First Patient in Investigator-Sponsored Phase 2 Study of Mocetinostat in Non-Hodgkin's …

| January 6, 2015 | 0 Comments

SAN DIEGO, Jan. 6, 2015 /PRNewswire/ —

Continue Reading

Mesothelioma Research Foundation’s Message to the Pharmaceutical Industry

| December 26, 2014 | 0 Comments

Last month, the chair of the board of directors of the Mesothelioma Applied Research Foundation and oncologist at Memorial Sloan Kettering Cancer Center, Lee M. Krug, MD, penned a blog post message to the pharmaceutical industry that recruitment of patients with mesothelioma to large trials is feasible, and encouraging them to pursue drug development in that uncommon disease. (PRWeb December 26 …

Continue Reading

New Clinical Data Supports the Use of FoundationOne® Heme to Enable Informed Treatment Decisions in a Wide Range of …

| December 9, 2014 | 0 Comments

Foundation Medicine, Inc. today announced new data demonstrating that FoundationOne® Heme, developed in collaboration with Memorial Sloan Kettering Cancer Center, provides critical genomic information that can impact prognosis, influence therapeutic strategy and even refine conventional pathologic diagnosis in patients with a wide range of hematologic malignancies.

Continue Reading

Actinium Pharmaceuticals Brief Report; Alpha Particles, the Cancer Killers by Small Cap Traders

| November 7, 2014 | 0 Comments

Actinium Pharmaceuticals Incorporation (ATNM) is a public biopharmaceutical company specialized in the development of cancer drugs. The Company's product candidates are based on its patented technology co-developed with Memorial Sloan Kettering Cancer Center (MSKCC) for combining the cancer targeting precision of monoclonal antibodies (mAb) for targeting specific types of cells with the power of …

Continue Reading

Hartford HealthCare Launches Alliance With Leading NYC Cancer Center

| September 16, 2014 | 0 Comments

HARTFORD — The alliance Hartford HealthCare announced a year ago with Memorial Sloan Kettering to tap into the leading New York cancer center's research and treatment capabilities is moving forward.

Continue Reading

Hartford HealthCare Launches Alliance With Memorial Sloan Kettering Cancer Center

| September 16, 2014 | 0 Comments

The alliance Hartford HealthCare announced a year ago with Memorial Sloan Kettering to tap into the leading New York cancer center's research and treatment capabilities is moving forward.

Continue Reading

SELLAS Life Sciences Group Signs Exclusive License Agreement for Global Rights on Development and Commercialization of …

| September 4, 2014 | 0 Comments

NEW YORK, Sept. 4, 2014 /PRNewswire/ — SELLAS Life Sciences Group (SELLAS), a Swiss-based development-stage biopharmaceutical company today announced that it has signed an exclusive global collaboration and license agreement with Memorial Sloan Kettering Cancer Center (MSK) for the development, marketing, and commercialization of MSK's proprietary WT1 cancer vaccine.   “This collaboration …

Continue Reading